EDNRB
Endothelin receptor type B
As of the edition of 20 October 2026, EDNRB (endothelin receptor type B, UniProt P24530) has 9 drugs tested at it and 9 companies on the list, 2 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P24530
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 17
- Disease areas
- Lungs and airways; Heart and blood vessels; Skin and connective tissue; Inherited and neonatal; Nervous system; Cancer; Digestive system; Hormones
- Registered trials of its drugs
- 250
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 2 |
| Went quiet | 1 |
| Stopped | 1 |
| Withdrawn from market | 1 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Bosentan | Marketed | Phase 4 | none listed |
| Macitentan | Marketed | Phase 4 | Ends 2031 |
| Ambrisentan | Marketed | Phase 4 | none listed |
| Sitaxentan | Withdrawn from market | Phase 3 | none listed |
| Aprocitentan | Marketed | Phase 3 | Ends 2038 |
| Sovatelitide | Active | Phase 4 | none listed |
| BQ 788 | Active | Phase 2 | none listed |
| Tezosentan | Stopped | Phase 3 | none listed |
| RG-7636 | Went quiet | Phase 1 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 3 |
| Engaged | 2 |
| Undetermined | 2 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Idorsia Pharmaceuticals | Route B |
| Roche | Route A |
| Idorsia Pharmaceuticals Deutschland | Route B |
The other 6 companies at EDNRB
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at EDNRB, ranked, with the facts behind eachRequest access. Nothing is shown until you do.